Case Study 4: Examining New Identity (ID) Assays for Multivalent mRNA Vaccines

Time: 3:15 pm
day: Focus Day


  • Identity (ID) assay required as both in-process and final releasing assays for mRNA vaccines
  • Current progress and challenges of sequence methods as orthogonal approaches for multivalent mRNA ID assay
  • Two newly developed ID methods demonstrated their advantages including shortened lead time, flexibility as a platform method and low requirement for in-house lab capacity